Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Tromsø – page 7

142 clinical trials in Tromsø, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Tromsø at a glance
142
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

142 trials in Tromsø

Open in trial search

Malignant melanoma

Recruiting

Study on Short vs. Long Immunotherapy with Pembrolizumab and Nivolumab for Patients with High-Risk Skin Melanoma After Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:North Estonia Medical Centre Foundation

Acute lymphocytic leukaemia

Recruiting

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Dementia with Lewy bodies

Recruiting

Study of Ambroxol Treatment in People with Early Stage or Mild Lewy Body Dementia

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ambroxol Hydrochloride
  • Sponsor:Helse Fonna HF

Drug dependence

Recruiting

Study of diazepam and oxazepam in patients with benzodiazepine and opioid dependence who are receiving opioid agonist therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Diazepam
  • Sponsor:Helse Bergen HF

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Assessing tumor dose dynamics and pre‑treatment dosimetry of lutetium‑177 PSMA‑I&T in men with metastatic castration‑resistant prostate cancer

Not yet recruiting
InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) zadavotide guraxetan
  • Sponsor:Universitetssykehuset Nord-Norge HF

Non-small cell lung cancer

Not yet recruiting

Phase II Randomized Trial of Adjuvant Durvalumab Immunotherapy After Neoadjuvant Chemoimmunotherapy in Patients With Resectable Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oslo University Hospital HF

Coronary artery disease

Not yet recruiting

Continuing vs Stopping Acetylsalicylic Acid in Elderly Patients with Chronic Coronary Syndrome (Secondary Prevention): A Randomized Trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vestre Viken HF

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Not yet recruiting
Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Cluster headache

Not yet recruiting

A Study of Candesartan to Prevent Chronic Cluster Headache Attacks in Adults with Chronic Cluster Headache

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Candesartan
  • Sponsor:Helse Bergen HF

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Tromsø

What the registry says about research in the country

01 Oncology Studies

Multiple clinical trials focusing on innovative cancer treatments, including research on rare cancers, hepatoblastoma, and testicular cancer. Studies explore personalized treatment approaches and drug efficacy evaluation.

  • Breast Cancer Biomarkers
  • Pediatric Liver Tumors
  • Advanced Endometrial Cancer

Novel therapeutic strategies and targeted treatments are being investigated to improve patient outcomes.

02 Neurological Disorders

Research focusing on Alzheimer's disease treatment and acute ischemic stroke management. Studies evaluate new drug comparisons and therapeutic interventions.

  • Early Alzheimer's Treatment
  • Stroke Thrombolysis
  • Cognitive Function

Emphasis on developing effective therapeutic approaches for neurodegenerative conditions.

03 Pediatric Medicine

Comprehensive studies addressing various childhood conditions, including acute wheezing, leukemia, and respiratory infections.

  • Childhood Respiratory Infections
  • Pediatric Cancer Treatment
  • Inflammatory Conditions

Focus on improving treatment outcomes in young patients through innovative therapeutic approaches.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.